Oncolytic HSV-1 rRp450

Known as: rRp450 
A gene therapy agent containing an attenuated, replication-competent, genetically engineered mutant form of the Herpes simplex virus 1 (HSV-1) strain… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2017
0119992017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Pediatric brain tumors including medulloblastoma and atypical teratoid/rhabdoid tumor are associated with significant mortality… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Oncolytic herpes simplex virus (oHSV) mutants are under development as anticancer therapeutics. One such vector, rRp450, is ICP6… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2002
2002
BACKGROUND Herpes simplex virus 1 (HSV-1) infection of cancer cells results in viral replication with cell destruction and… (More)
Is this relevant?
2001
2001
rRp450 is an oncolytic herpesvirus that expresses the CYP2B1 cDNA, responsible for bioconverting cyclophosphamide (CPA) into the… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Cellular delivery of a replication-conditional herpes simplex virus type 1 (HSV-1) vector provides a means for gene therapy of… (More)
Is this relevant?
2000
2000
Herpes simplex virus type 1 (HSV-1) replication within tumors can mediate tumor regression (oncolysis). The genetically… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Multimodal therapy is generally more effective than single-agent treatment for cancer. rRp450 is an engineered herpes simplex… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?